| Assessment Status | Rapid Review complete |
| HTA ID | 21017 |
| Drug | Conestat alfa |
| Brand | Ruconest® |
| Indication | For the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. |
| Assessment Process | |
| Rapid review commissioned | 21/04/2021 |
| Rapid review completed | 02/06/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that conestat alfa not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations January 2022.
